We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Rtw Biotech Opportunities Ltd | LSE:RTWG | London | Ordinary Share | GG00BKTRRM22 | ORD NPV (GBP) |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 116.00 | 112.00 | 120.00 | 0.00 | 00:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Trust,ex Ed,religious,charty | 4.17M | -4.76M | -0.0123 | -125.20 | 447.98M |
From Nov 2023 to Nov 2024
TIDMRTW
RNS Number : 6976W
RTW Biotech Opportunities Ltd
14 December 2023
LEI: 549300Q7EXQQH6KF7Z84
14 December 2023
RTW Biotech Opportunities Ltd
Monthly Valuation Update, November Factsheet
+11.9% NAV movement for the month
RTW Biotech Opportunities Ltd (the "Company") announces that the unaudited net asset value attributable to the ordinary shares of the Company at the close of business on 30th November 2023 (the "NAV") was US$347.7 million, or US$1.65 per ordinary share, +11.9% from the previous month.
The monthly factsheet is available on the Company's website:
https://www.rtwfunds.com/rtw-biotech-opportunities-ltd/factsheets-letters/
For Further Information:
RTW Investments, LP +44 20 7959 6361 Woody Stileman, Managing Director Krisha McCune, Director, Client Service Buchanan +44 20 7466 5107 Charles Ryland Henry Wilson George Beale Numis +44 20 7260 1000 Freddie Barnfield Nathan Brown Euan Brown BofA Securities +44 20 7628 1000 Edward Peel Kieran Millar Cadarn Capital +44 73 6888 3211 David Harris Elysium Fund Management Limited Joanna Duquemin Nicolle, Chief Executive Officer Sadie Morrison, Managing Director +44 (0) 14 8181 0100 Morgan Stanley Fund Services USA LLC +1 914 225 8885
About Biotech Opportunities Ltd:
RTW Biotech Opportunities Ltd (LSE: RTW & RTWG) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Biotech Opportunities Ltd invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives. RTW Biotech Opportunities Ltd is managed by RTW Investments, LP, a leading healthcare-focused entrepreneurial investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.
Visit the website at www.rtwfunds.com/rtw-biotech-opportunities-ltd for more information.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
MSCTJBFTMTABBLJ
(END) Dow Jones Newswires
December 14, 2023 02:00 ET (07:00 GMT)
1 Year Rtw Biotech Opportunities Chart |
1 Month Rtw Biotech Opportunities Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
